A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and leukemia group B (CALGB) 8931

Controlled Clinical Trials

Volumn 18, Issue 4, 1997, Pages 286-300

  Herndon II, James E ^a   Fleishman, Stewart ^b   Kosty, Michael P ^c   Green, Mark R ^d  

^a DUKE UNIVERSITY   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c SCRIPPS CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trial; Hydrazine sulfate; Non small lung cancer; Quality of life

Indexed keywords

CISPLATIN; HYDRAZINE SULFATE; PLACEBO; VINBLASTINE;

ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HUMAN; LEUKOPENIA; LONGITUDINAL STUDY; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; NAUSEA; NEUTROPENIA; PSYCHOMETRY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSORY NEUROPATHY; STATISTICAL MODEL; SURVIVAL; VOMITING;

EID: 0030852126     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/0197-2456(96)00116-X     Document Type: Article

References (23)

1. Gotay CC, Korn EL, McCabe MS, Moore TD, Cheson BD. Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. JNCI 1992;84:575-579.
2. Gotay CC, Korn El, McCabe MS, Moore TD, Cheson BD. Building quality of life assessment into cancer treatment studies. Oncology 1992;6:25-28.
3. Nayfield SG, Hailey BJ. Quality of life assessment in cancer clinical trials: report of the workshop on quality of life research in cancer clinical trials. National Cancer Institute, Bethesda, MD, 1990.
4. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL, Crowley J. Quality of life end points in cancer clinical trials: review and recommendations. JNCI 1989;81:485-495.
5. Kosty MP, Fleishman SB, Herndon JE II, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1994:12:1113-1120.
6. Cancer Facts and Figures - 1996. American Cancer Society, Atlanta, GA, 1996.
7. Chlebowski RT, Bulcavage L, Grosvenor M, et al. Hydrazine sulfate in cancer patients with weight loss: a placebo-controlled clinical experience. Cancer 1987;59:406-410.
8. Chlebowski RT, Bulcavage L, Grosvenor M, et al. Hydrazine sulfate influence on nutritional status and survival in non-small cell lung cancer. J Clin Oncol 1990;8:9-15.
9. Zubrod CG, Schneidermann M, Frei M, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylen thiophosphoramide. J Chron Dis 1960;11:7-33.
10. Piantadosi S. Hazards of small clinical trials. J Clin Oncol 1990;8:1-3.
11. Aaronson NK, Bullinger M, and Ahmedzai S. A modular approach to quality-of-life assessment in cancer clinical trials. Recent Results in Cancer Research 1988;11:231-249.
12. Aaronson NK, Ahmedzai S, Bullinger M, et al. The EORTC core quality-of-life questionnaire: interim results of an international field study. In: D. Osoba, ed. Effect of Cancer on Quality of Life. Boston, MA: CRC Press; 1991, 185-203.
13. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. JNCI 1993;85:365-376.
14. Bergman C, Aaronson NK, Ahmedzai S, Kaasa S. The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in the lung cancer clinical trials. Eur J Cancer 30A:635-642.
15. Broadhead WE, Gehlbach SH, de Gruy FV, et al. The Duke-UNC functional social support questionnaire. Measurement of social support in family medicine patients. Medical Care 1988;26:709-723.
16. Laird NM. Missing data in longitudinal studies. Stat Med 7:305-315.
17. Diggle P, Kenward MG. Informative drop-out in longitudinal data analysis. Stat Med 1994;43:49-93.
18. Wu MC, Carroll RJ. Estimation and comparison of changes in the presence of informative right censoring by modeling the censoring process. Biometrics 44:175-188.
19. Wu MC and Bailey K. Analysing changes in the presence of informative censoring caused by death and withdrawal. Stat Med 1988;7:337-346.
20. Wu MC, Bailey KR. Estimation and comparison of changes in the presence of informative right censoring: conditional linear model. Biometrics 45:939-955.
21. Schluchter, MD. Methods for the analysis of informatively censored longitudinal data. Stat Med 1992;11:1861-1870.
22. Mori W, Woodworth GG, Woolson RF. Application of empirical Bayes inferences to estimation of rate of change in the presence of informative right censoring. Stat Med 1992;11:621-631.
23. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. New York: Oxford University Press; 1994.